Cord Blood Transplantation for Blood Cancers
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to get a clear answer.
What data supports the effectiveness of the treatment Cyclophosphamide, Fludarabine, and Thiotepa for blood cancers?
Research shows that using Cyclophosphamide, Fludarabine, and Thiotepa in cord blood transplants can lead to high rates of successful engraftment (when transplanted cells start to grow and make healthy blood cells) and improved survival rates in patients with blood cancers. These drugs, when used together, have been associated with lower relapse rates and better overall survival compared to some other treatment regimens.12345
Is cord blood transplantation safe for treating blood cancers?
Cord blood transplantation has been studied for safety, showing that while it can lead to complications like graft-versus-host disease (a condition where the donor cells attack the recipient's body) and organ toxicity, many patients achieve successful engraftment (when the transplanted cells start to grow and make healthy blood cells). Treatment-related deaths can occur, but survival rates are promising, indicating it is generally safe with careful monitoring.23567
How is the cord blood transplantation treatment with Cyclophosphamide, Fludarabine, and Thiotepa different from other treatments for blood cancers?
This treatment is unique because it uses umbilical cord blood from unrelated donors, which can be an option for patients who do not have a matched donor. The combination of Cyclophosphamide, Fludarabine, and Thiotepa is part of a conditioning regimen that prepares the body for the transplant, aiming to improve survival rates in patients with advanced blood cancers.2891011
What is the purpose of this trial?
The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.
Research Team
Warren Fingrut, MD
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for patients aged 0-60 with high-risk blood cancers who have relapsed after their first stem cell transplant. They must be in good physical condition, with a Karnofsky score of at least 70%, proper heart and kidney function, and specific diagnoses like AML or ALL in remission. Pregnant individuals, those not using contraception, or with uncontrolled infections/GVHD can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Conditioning Therapy
Participants receive intermediate-intensity conditioning therapy prior to cord blood transplant
Cord Blood Transplantation
Participants undergo cord blood transplantation to control high-risk hematological malignancies
Follow-up
Participants are monitored for safety, effectiveness, and adverse events after transplantation
Treatment Details
Interventions
- Cyclophosphamide
- Fludarabine
- Thiotepa
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor